The aim of the present study was to investigate whether secretome obtained from normoxia-preconditioned human mesenchymal stem cells causes attenuation of traumatic brain injury (TBI), induced by fluid percussion injury.
T raumatic brain injury (TBI), the leading cause of morbidity and mortality in young adults and children, is a major public health problem globally. Despite adequate treatment provided, traumatic head injury commonly causes neuronal loss and apoptosis, leading to long-term neurologic deficient.
1Y4
Until now, patients with TBI are still inadequately treated because of the lack of effective therapies. 5Y7 To develop novel therapeutic strategies or to find new effective therapeutic drugs is an important issue.
Mesenchymal stem cells (MSCs) were first identified by Friedenstein et al. 8 as stromal cells from the bone marrow and described as spindle-shaped cells in culture. MSCs are selfrenewing, clonal precursors of nonhematopoietic tissue, which can be cultured in vitro while retaining the potential to give rise to osteoblasts, 9 chondrocytes, 9 astrocytes, 10 neurons, 11 and skeletal muscle. 12 They also have the ability to secrete a variety of growth factors 11 that result in improving functional outcome in the rat model of TBI. Many investigators have reported that transplanted MSCs into the central nervous system significantly promote neuronal recovery in animal models of trauma.
13Y15
However, decisive evidence indicated that tissue regeneration by MSCs may not be the main source of functional recovery since only a small proportion of transplanted MSCs appear to differentiate into neurons and astrocytes. 16Y18 Furthermore, the death of transplanted cells and consequential immune reactions add burdens to the host tissue that has already been compromised by cellular debris. 19, 20 Recent studies suggest that the therapeutic effects of stem cell transplantation following TBI are mediated by paracrine factors. Those alter the tissue microenvironment and may play a more prominent role than their transdifferentiation in effecting tissue repair. 21 These results suggest that these paracrine factors obtained from MSC could be a promising strategy for rescue neurons following TBI.
It was shown that stimulating vascular endothelium growth factor (VEGF) production in the injured brain attenuated cerebral infarction and apoptosis and restored normal behavioral function in TBI rats. 3, 4, 22 Furthermore, VEGF is a neurotrophic factor that could undergo stimulating production in traumatic brain area after MSC treatment. 11, 23 These data imply that agents with the effects on promoting neurotrophic factor production could be neuroprotective agents.
The harmful effect of stem cell transplantation has been reported for its tumorigenicity character. The possibility of teratoma formation in the cerebrum after stem cell transplantation remains unpredictable. 24 Another disadvantage of stem cell transplantation is the pulmonary passage or so called pulmonary first-pass effect. This is a major obstacle for intravenous stem cell delivery. Most of the intravenous transplanted stem cells are lodged in lung tissue. Besides, the therapeutic effect of transplanted stem cells is difficult to predict; the optimal dosage adjustment is also more and more difficult. 25 Up to now, therapeutic application of secretome obtained from hMSC has not been performed in the field of TBI. No direct mechanism has been proposed for the effect of secretome on experimental TBI model. In this study, we hypothesize that secretome from hMSC may have therapeutic effect on TBI based on its characteristic paracrine effect on fluid percussion injury (FPI)Yinduced cell damage and apoptosis. To deal with this hypothesis, experiments were performed to assess the therapeutic effects of secretome on the brain neuronal cell loss, apoptosis, and neurotrophic factors VEGF expression in the area of ischemia cortex by immunofluorescence methods. In addition, we also compared the motor deficits and cerebral infarction volume during TBI in rat with or without secretome therapy.
MATERIALS AND METHODS

Cell Culture
Human MSCs (hMSCs) were isolated from commercially available bone marrow aspirates (Clonetics-Poietics, Walkersville, MD) and grown and characterized as previously reported. Cells were used for experiments during passages 3 to 7. Cells released by cell dissociation buffer (Gibco, Grand Island, NY) were phenotyped using a FACS flow cytometry (Beckman Coulter, Indianapolis, IN) and monoclonal antibodies. Antibodies for CD34, CD45, CD90, and CD73 were purchased from BD Pharmingen (catalog numbers 55824, 34796, 555595, 550257) (BD Pharmingen, San Jose, CA) and CD105 from R&D System (10971A) (R&D, Minneapolis, MN). In vitro differentiation assays were performed as per manufacturer's instructions (Clonetic-Poietic, Walkersville, MD). Cultured hMSCs were cultured in Dulbecco's Modified Eagle's Medium (DMEM)Ylow glucose supplemented with 10% MSC-qualified fetal bovine serum during the entire experimental period.
Preparation Delivery of Conditioned Media
hMSCs were isolated from commercially available bone marrow aspirates and grown and characterized as previously reported. Conditioned medium was prepared by collecting serum-free medium (supplemented with 0.05% bovine serum albumin to prevent protein aggregation) after 24-hour culture of different cell masses. Most of the experiments were performed with the optimal cell mass of 2 Â 6 10 cells. The medium was concentrated, approximately 25 -fold, using ultrafiltration units (Amicon Ultra-PL 3, Millipore, Bedford, MA) with a 3-kD molecular weight cut-off. For fractionation experiments, concentrated medium was passed over a heparin-agarose column, and the flow-through and eluted fractions were collected and reconcentrated using the same ultrafiltration system.
Animals
Adult male Sprague-Dawley rats weighing 275 (16) g were used in these experiments. Animals were kept under a 12/12-hour light/dark cycle and allowed free access to food and water. All experimental procedures conformed to the National Institutes of Health guidelines and were approved by the Chi Mei Medical Center Animal Care and Use Committee to minimize discomfort in the animals during surgery and in the recovery period.
TBI
Animals were given generalized anesthesia with sodium pentobarbital (25 mg/kg, intraperitoneal; Sigma Chemical Co., St. Louis, MO) and a mixture containing ketamine (44 mg/kg, intramuscular; Nankuang Pharmaceutical, Tainan, Taiwan), atropine (0.062633 mg/kg, intramuscular; Sintong Chemical Industrial Co., Kaoshiung, Taiwan), and xylazine (6.77 mg/kg, intramuscular; Bayer, Monheim, Germany). They were placed in a stereotaxic frame, and the scalp was incised sagittally. Animals were subjected to a lateral FPI to induce TBI. 26 After an incision in the scalp was made, a 4.8-mm circular craniotomy was performed midway between lambda and bregma, 3.0 mm to the right of the central suture. A modified Leur lock connector (trauma cannula), 2.6 mm inner diameter, was secured into the craniotomy with cyanoacrylic adhesive and dental acrylic. A moderate FPI (2.2 atm) was produced by rapidly injecting a small volume of saline into the closed cranial cavity with a fluid percussion device (VCU Biomedical Engineering, Richmond, VA). The animal was removed from the device, the acrylic was removed, and the incision was sutured. Each injured and shaminjured animal for fluid percussion model was evaluated closely immediately after TBI for behavioral recovery.
Delivery of Conditioned Media
Animals were randomly assigned to sham-operated group (n = 8), TBI groups treated with control DMEM medium (culture medium, 1 mL/kg, intravenous) (n = 8), or TBI group immediately (G5 minutes) treated with secretome (DMEM medium 1 mL/kg + secretome 500 Hg) via jugular vein injection (n = 8). All tests were run blinded, and the animal codes were revealed only at the end of the behavioral and histologic analyses. Animals used for histologic or behavioral studies were provided food and water ad libitum throughout the study.
Cerebral Infarction Assay
The triphenyltetrazolium chloride (TTC) staining procedures followed those described elsewhere. 4 All animals were killed at Day 3 after FPI. Under deep anesthesia (sodium pentobarbital, 100 mg/kg, intraperitoneal) animals were perfused intracardially with saline. The brain tissue was then removed, immersed in cold saline for 5 minutes, and sliced into 2.0-mm sections. The brain slices were incubated in 2% TTC dissolved in phosphate-buffered saline (PBS) for 30 minutes at 37-C and then transferred to 5% formaldehyde solution for fixation. The volume of infarction, as revealed by negative TTC staining results indicating dehydrogenase-deficient tissue, was measured in each slice and summed using computerized planimetry (PC-based Image Tools software, Buckinghamshire, UK). The volume of infarction was calculated as 2 mm (thickness of the slice) Â (sum of the infarction area in all brain slices [mm incubated in 2-mol/L HCl for 30 minutes, rinsed in 0.1-mol/L boric acid (pH 8.5) for 3 minutes at room temperature and then incubated with primary antibodies in PBS containing 0.5% normal bovine serum at 4-C overnight. After being washed in PBS, the sections were incubated with secondary antibodies for 1 hour at room temperature. The following antibodies were used in this study: mouse anti-VEGF, or mouse antiYneuronal-specific nuclear protein (NeuN) antibody in 1:200 dilution and then detected with Alexa-Fluor, 568 goat antimouse (immunoglobulin G) antibody. The sections were then washed in PBS/0.6% Triton X-100 and were incubated with FITC-conjugated (fluorescein) anti-rabbit immunoglobulin G in 1% BSA/PBS/0.1% Triton X-100 for 60 minutes. They were mounted with antifade mounting media. The numbers of labeled cells was calculated in five coronal sections from each rat and expressed as the mean number of cells per section. For negative coronal sections, all procedures were performed in the same manner without the primary antibodies.
Neuronal Apoptotic Assay
Cellular identification of apoptotic cells was made by double staining with terminal deoxynucleotidyl transferaseYmediated dUTP-biotin nick end labeling (TUNEL) and the neuronal nuclear marker NeuN at 3 days after TBI. TUNEL staining was performed using an in situ cell death detection kit according to the instructions of the manufacturer. The kit contained terminal deoxynucleotidyl transferase, which catalyzes polymerization of fluorescein dUTP onto free 3?-OH DNA ends in a template-dependent manner. TUNEL-positive cells are identified directly by fluorescence of incorporated dUTP. Double staining with anti-Neu antibody. 27 The number of TUNEL/NeuNYpositive cells in the samples was measured in each slice and summed using computerized planimetry (PC-based Image Tools software).
Motor Function Test
The inclined plane was used to measure limb strength. Animals were placed, facing right and then left, perpendicular to the slope of a 20 Â 20-cm buffer ribbed surface of an inclined plane starting at an angle of 55 degrees. 28 The angle was increased or decreased in 5-degree increments to determine the maximal angle an animal could hold on to the plane. Data for each day were the means of left-and right-side maximal angle. Measurements of motor deficits were conducted daily, but only the fourth day values were presented.
RESULTS
Identification of hMSCs by Flow Cytometry
By using flow cytometry analysis, it shows the surface markers of our detected cells presenting with CD73, CD90, and CD105 positivity as well as CD34 and CD45 negativity (Fig. 1) . These results confirmed our experimental cells are MSC and without hematopoietic cell contamination.
Secretome From MSCs Attenuates FPI-Induced Cerebral Infarction Volume
The TTC-stained sections at 3 days after TBI showed a significant increase (p G 0.05; n = 8) in the infarcted area of the vehicle-treated TBI as compared with those of sham TBI controls. The TBI-induced infarction volume was significantly decreased (p G 0.05; n = 8) by secretome (500 Hg, intravenous) treatment (Fig. 2) .
Secretome From MSCs Attenuates FPI-Induced Apoptosis in the Cortex
In the TUNEL assay at 3 days after FPI, the positive apoptotic cells in the ischemia cortex were significantly increased (p G 0.05; n = 8) compared with those in the sham controls. The increased number of positive apoptotic cells in the ischemia cortex resulting from FPI inducement was significantly reduced (p G 0.05; n = 8) by secretome (500 Hg, intravenous) therapy (Fig. 3) .
Secretome From MSCs Attenuates FPI-Induced Neuronal Loss in the Cortex
In the NeuN-stained assay at 3 days after FPI, the positive neuronal cells in the ischemia cortex were significantly decreased (p G 0.05; n = 8) compared with those in the sham controls. However, the decreased number of neuronal positive cells in the ischemia cortex resulting from FPI inducement was significantly increased (p G 0.05; n = 8) by secretome (500 Hg intravenous) treatment (Fig. 4) .
Secretome From MSCs Attenuates FPI-Induced Neuronal Apoptosis in the Cortex
In the TUNEL plus NeuNYstained at 3 days after FPI, the positive neuronal apoptotic cells in the ischemia cortex were significantly increased (p G 0.05; n = 8) compared with those in the sham controls. The increased number of neuronal apoptotic positive cells in the ischemic cortex resulting from FPI inducement was significantly reduced (p G 0.05; n = 8) by secretome (500 Hg. intravenous) therapy (Fig. 5) .
Secretome From MSCs Further Enhanced FPI-Induced VEGF Expression in the Cortex
Three days after TBI, the VEGF-positive expression cells in the ischemia cortex were significantly increased (p G 0.05; n = 8) compared with those in the sham controls. However, the increased number of VEGF-positive expression cells in the cortex resulting from FPI inducement was further significantly increased (p G 0.05; n = 8) by secretome (500 Hg, intravenous) therapy (Fig. 6 ).
Secretome From MSCs Attenuates FPI-Induced Motor Deficits
The motor function was evaluated by maximal grip angle in an inclined plane model. The maximal grip angle at 3 days after FPI injury was significantly decreased (p G 0.05; n = 8) compared with that of the sham-operated controls (55 degrees vs. 45 degrees). The maximal grip angle that the FPI-induced motor dysfunction was significantly increased (45 degrees vs. 51 degrees) (p G 0.05; n = 8) by secretome (500 Hg, intravenous) treatment (figure not shown).
DISCUSSIONS Novelty of the Present Study
In this present study, we used secretome obtained from normoxia-preconditioned hMSCs because the neuroprotective effects of transplanted MSCs on neural injury are well documented. 11 It is important to test whether secretome obtained from normoxia-preconditioned hMSCs provide therapeutic benefit before they can be used as a potential treatment of TBI in humans. To our knowledge, this is the first study to present neuroprotective effects using secretome injection in traumatic central nervous system injury. Our group was the first one to report effective treatment of TBI with MSC secretion.
These data extend our knowledge on hMSC in traumatic central nervous system injuries, and it is to be hoped that it will serve as a foundation for future studies on the importance of the secretome therapy in TBI.
Identifying the hMSC Using Flow Cytometry
Bone marrowYderived MSCs express the surface markers CD29, CD73, CD90, CD105, CD106, CD140b, and CD166 but lack CD31, CD45, CD34, and CD133. 29 Identifying the character of hMSC in our study is an important issue before harvesting the secretome from hMSC. The CD73, CD90, and CD105 are cell surface markers for hMSC, and CD34 and CD45 are cell surface markers for hematopoietic cells. Figure 1 shows the surface markers of our detected cells presenting with CD73, CD90, and CD105 positivity as well as CD34 and CD45 negativity. These results confirmed that our experimental cells are MSC and without hematopoietic cell contamination.
The Neuroprotective Effects of Secretome Injection After TBI
The present results demonstrated that intravenously injected single-dose 500-Hg secretome therapy caused attenuation of TBI-induced neuronal apoptosis (evidenced by increased numbers of both NeuN-and TUNEL-positive cells), neuronal loss (evidenced by decreased numbers of NeuN-positive cells), and cerebral infarction volume (evidenced by TTC staining) when evaluated 3 days after FPI. It also displayed reduced motor deficits (evidenced by increased maximum grasp angle in inclined plane test) and increased neurotrophic factor production (evidenced by enhanced VEGF-positive expression cells). These results are consistent with previous studies using MSC transplantation intracerebral or intravenous injection. 13Y15,17 Again, it makes sense that secretome injection therapy is a promising strategy for rescuing neurons following TBI.
Secretome Therapy Significantly Decrease Apoptotic Cells After TBI Previous study suggests that MSCs injected intravenously significantly decrease apoptotic cells after TBI. 23 The mechanisms of inhibition of apoptotic neuronal cell death could be through augmented secretion of neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor as well as increased Akt activity and decreased caspase 3 cleavage, which subsequently results in the functional recovery. 23, 30 In our study, similar to previous report that treated with hMSC transplantation, intravenously injected secretome obtained from hMSC significantly decreased apoptotic cells in the injured cortex after TBI. However, the mechanisms signal pathway involved is needed to be evaluated in the future.
VEGF as a Neuroprotective/Neurotrophic Factor
VEGF up-regulation after TBI stress has been reported. 3, 4, 31 Evidence has accumulated to indicate that the damaged brain environment promotes a responsive secretion of a wide array of neurotrophins and bioactive factors by MSCs after TBI. 11 In our data, secretome therapy reduced cell apoptosis and improved the recovery from TBI in rats. In an effort to investigate the mechanism by which secretome induce functional recovery following TBI, we examined the VEGF expression in the injured cortex. Similar to MSC therapy, secretome obtained from normoxia-preconditioned hMSC enhancing VEGF expression cells may have improved behavioral outcome and cerebral infarction after FPI. These results supported the findings that VEGF could be one neurotrophic/neuroprotective factor involved in preventing apoptosis. 32 However, the effect of VEGF on angiogenesis and neurogenesis after secretome therapy are needed to be evaluated in the future.
33,34
Normoxia-or Hypoxia-Preconditioned Medium
The migration of injected MSCs are dependent on the specific signals, for example, via stromal-derived factor 1 expressed in astrocytes, neurons and endothelial cells, and CXCR4 (receptor of stromal-derived factor 1) expressed in MSCs. These signals present in the local microenvironment where hypoxia or ischemia result in damaged brain tissue. 35 hypoxic preconditioning (1Y3% oxygen) hMSC has been shown to be neuroprotective against ischemic brain injury. 36, 37 Benefits of hypoxic preconditioning owing to the up-regulation of endogenous prosurvival and regenerative mechanisms such as VEGF secretion can be enhanced by hypoxia and by overexpression of hypoxia-inducible factor 1.
38Y40 However, in our study, we used normoxia (21% O 2 )Ypreconditioned hMSC for 24 hours then collected and condensed the secretome for intravenous injection after TBI. The results are promising and encouraging to us.
Our study clearly shows that the intravenous injection of secretome obtained from normoxia-preconditioned hMSCs can be a potential treatment of TBI. Application of MSC secretions could enable us to avoid some of the limiting factors associated with cell therapy, such as immune incompatibility, tumorigenicity, pulmonary first-pass effect, costs, and waiting time for ex vivo expansion. However, the components of secretome, except VEGF, were not well-evaluated in the present study. It should be further elucidated by proteomics analysis or other method in future researches.
CONCLUSION
Based on our results, we concluded that intravenous injection of secretome from normoxia-preconditioned hMSC administered as a single dose of 500 Hg may ameliorate TBI in rats by reducing neuronal cell loss and apoptosis, and promoting VEGF production result in improving functional outcome. We also recommend that secretome from normoxiapreconditioned hMSC could be a promising treatment strategy for TBI. 
